669 related articles for article (PubMed ID: 30486882)
1. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
2. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
[TBL] [Abstract][Full Text] [Related]
3. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
[TBL] [Abstract][Full Text] [Related]
4. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
6. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
7. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
8. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.
Panza F; Frisardi V; Imbimbo BP; Seripa D; Paris F; Santamato A; D'Onofrio G; Logroscino G; Pilotto A; Solfrizzi V
Curr Alzheimer Res; 2011 Dec; 8(8):808-17. PubMed ID: 21592055
[TBL] [Abstract][Full Text] [Related]
9. [Aβ immunotherapy for Alzheimer's disease].
Sakai K; Yamada M
Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
[TBL] [Abstract][Full Text] [Related]
10. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
11. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.
Adolfsson O; Pihlgren M; Toni N; Varisco Y; Buccarello AL; Antoniello K; Lohmann S; Piorkowska K; Gafner V; Atwal JK; Maloney J; Chen M; Gogineni A; Weimer RM; Mortensen DL; Friesenhahn M; Ho C; Paul R; Pfeifer A; Muhs A; Watts RJ
J Neurosci; 2012 Jul; 32(28):9677-89. PubMed ID: 22787053
[TBL] [Abstract][Full Text] [Related]
12. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.
Fuller JP; Stavenhagen JB; Christensen S; Kartberg F; Glennie MJ; Teeling JL
Acta Neuropathol; 2015 Nov; 130(5):699-711. PubMed ID: 26433971
[TBL] [Abstract][Full Text] [Related]
13. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
14. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.
Roher AE; Maarouf CL; Daugs ID; Kokjohn TA; Hunter JM; Sabbagh MN; Beach TG
J Alzheimers Dis; 2011; 24(2):315-25. PubMed ID: 21263194
[TBL] [Abstract][Full Text] [Related]
15. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
[TBL] [Abstract][Full Text] [Related]
16. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
Nitsch RM; Hock C
Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L
Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
20. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
[No Abstract] [Full Text] [Related]
[Next] [New Search]
